{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:02:32Z","timestamp":1779350552174,"version":"3.51.4"},"reference-count":23,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,21]]},"abstract":"<p><bold>Objective.<\/bold> To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected.<\/p>\n<p><bold>Methods.<\/bold> Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG\u00ae ELISA kit was used.<\/p>\n<p><bold>Results.<\/bold> 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p &lt;0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset.<\/p>\n<p><bold>Conclusion.<\/bold> We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.<\/p>","DOI":"10.26633\/rpsp.2021.66","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:57:10Z","timestamp":1624291030000},"page":"1","source":"Crossref","is-referenced-by-count":6,"title":["Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina"],"prefix":"10.26633","volume":"45","author":[{"given":"Luz Mar\u00eda","family":"Rodeles","sequence":"first","affiliation":[{"name":"Universidad Nacional del Litoral, Santa Fe, Argentina."},{"name":"lmrodeles@fcm.unl.edu.ar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz Mar\u00eda","family":"Peverengo","sequence":"additional","affiliation":[{"name":"Universidad Nacional del Litoral, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Ben\u00edtez","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Benzaquen","sequence":"additional","affiliation":[{"name":"Sanatorio Diagn\u00f3stico, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila","family":"Serravalle","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Karina","family":"Long","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostina Daiana","family":"Benitez","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisina","family":"Zunino","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Lizarraga","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Hern\u00e1n","family":"Vicco","sequence":"additional","affiliation":[{"name":"Universidad Nacional del Litoral, Santa Fe, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11167","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020 Sep 1;173(5):362-367.","DOI":"10.7326\/M20-3012"},{"key":"ref2","unstructured":"World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection. May 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Seroepidemiology-2020.2 Access on March 30 2021."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. 2020 Jun 11;382(24):2302-2315.","DOI":"10.1056\/NEJMoa2006100"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020 Dec 4;370(6521):1227-1230.","DOI":"10.1126\/science.abd7728"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH, Aldrovandi GM, Yang OO. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020 Sep 10;383(11):1085-1087.","DOI":"10.1056\/NEJMc2025179"},{"key":"ref6","unstructured":"National Ministry of Health of Argentina. Consensus on the use of diagnostic tests for SARS-CoV-2. September 2020. Available from: https:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2020-09\/covid-19-consenso-sobre-uso-de-pruebas-diagnosticas-para-sars-cov-2.pdf. Access on March 30 2021."},{"key":"ref7","unstructured":"Ministerio de Salud de la Provincia de Santa Fe. Situaci\u00f3n epidemiol\u00f3gica COVID-19. Available from: www.santafe.gob.ar\/ms\/covid19\/ Access on March 30 2021."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ins\u00faa C, Stedile G, Figueroa V, Hern\u00e1ndez C, et al. Seroprevalence of SARS-CoV-2 antibodies among physicians from a children\u2019s hospital. Arch Argent Pediatr. 2020;118(6):381-385.","DOI":"10.5546\/aap.2020.eng.381"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Figar S, Pagotto V, Luna L, Salto J, Wagner Manslau M, Mistchenko A et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. medRxiv 2020.07.14.20153858","DOI":"10.1101\/2020.07.14.20153858"},{"key":"ref10","unstructured":"Consejo Nacional de Investigaciones Cient\u00edficas y Tecnol\u00f3gicas (CONICET), Fundaci\u00f3n Instituto Leloir, Universidad Nacional de San Mart\u00edn, Laboratorio Lemos S.R.L. COVID AR IgG. Enzyme immunoassay (ELISA) for the detection of specific IgG antibodies against the SARS-CoV-2 virus in human serum or plasma. ANMAT (PM-1545-4). Buenos Aires; 2020."},{"key":"ref11","unstructured":"Silva AP, Aguirre MF, Ballejo C, Marro MJ, Gamarnik AV, Vargas G, et al. Seroprevalencia de infecci\u00f3n por SARS-COV-2 en personal de salud de la regi\u00f3n sanitaria VIII, provincia de Buenos Aires, Argentina. Rev Argent Salud Publica. 2020; 12 Supl COVID-19:e14."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ojeda DS, Gonzales Lopez Ledesma MM, Pallares H, Costa Navarro G, Sanchez L, Perazzi B et al. Emergency Response for Evaluating SARS-CoV-2 Immune Status, Seroprevalence and Convalescent Plasma in Argentina. PLoS Pathog. 2021 Jan 14;17(1):e1009161. doi: 10.1371\/journal.ppat.1009161.","DOI":"10.1371\/journal.ppat.1009161"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz L, P\u00edfano M, Bolz\u00e1n A, Varela T, Comes Y, Specogna M et al. Vigilancia y Seroprevalencia: Evaluaci\u00f3n de anticuerpos IgG para SARS-Cov2 mediante ELISA en el barrio popular Villa Azul, Quilmes, Provincia de Buenos Aires, Argentina. DOI: 10.1590\/SciELOPreprints.1147","DOI":"10.1590\/SciELOPreprints.1147"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. J Infect. 2020 Dec;81(6):931-936.","DOI":"10.1016\/j.jinf.2020.10.011"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, Menzies D. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PLoS One. 2020 Nov 3;15(11):e0241536.","DOI":"10.1371\/journal.pone.0241536"},{"key":"ref16","unstructured":"Gaceta oficial de la provincia de Santa Fe. Ministerio de Salud. Decreto 0944-2020; Septiembre 7, 2020."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Li W, Zhang B, Lu J, Liu S, Chang Z, Peng C et al. Characteristics of Household Transmission of COVID-19. Clin Infect Dis. 2020 Nov 5;71(8):1943-1946.","DOI":"10.1093\/cid\/ciaa450"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Angulo-Baz\u00e1n Y, Solis S\u00e1nchez, G, Acosta J, Cardenas G, Jorge A, Cabezas C. Household transmission in people infected with SARS-CoV-2 (COVID-19) in Lima-Per\u00fa. medRxiv 2020.09.06.20189456.","DOI":"10.1101\/2020.09.06.20189456"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 Infections in Households-Tennessee and Wisconsin, April\u2013September 2020. Morb Mortal Wkly Rep. 2020;69:1631-1634.","DOI":"10.15585\/mmwr.mm6944e1"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Pierron D, Pereda-Loth V, Mantel M, Moranges M, Bignon E, Alva O et al. Smell and taste changes are early indicators of the COVID-19 pandemic and political decision effectiveness. Nat Commun. 2020 Oct 14;11(1):5152.","DOI":"10.1038\/s41467-020-18963-y"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Long QX, Tang, XJ, Shi QL, Li Q, Deng HJ et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Jun 26:1200\u20131204.","DOI":"10.1038\/s41591-020-0965-6"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020 Jun 16;52(6):971-977.e3.","DOI":"10.1016\/j.immuni.2020.04.023"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J et al. COVID-19 neutralizing antibodies predict disease severity and survival. medRxiv [Preprint]. 2020 Oct 20:2020.10.15.20213512.","DOI":"10.2139\/ssrn.3720298"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/54288\/v45e662021.pdf?sequence=1&isAllowed=y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:57:25Z","timestamp":1624291045000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/54288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":23,"alternative-id":["RPSP.2021.66"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2021.66","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}